- Active, not recruiting
NCT03836053: Phase 1b - AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma AMG420
Updated: Sep 2, 2022
AMG 420
To confirm the maximum tolerated dose (MTD) from the BI 836909 trial of 400 mcg/d, given as 28-day continuous intravenous infusion in patients with relapsed and/or refractory multiple myeloma, to test the 600 mcg/d dose, given as a 28-day continuous iV infusion.
Sponsor
Multiple locations
International Study
ClinicalTrials.gov Identifier: NCT03836053
Official Title: A Phase 1b Multicenter, Open-label, Expansion Study to Assess the Safety and Efficacy of AMG 420 as Monotherapy in Subjects With Relapsed and/or Refractory Multiple Myeloma
First Posted : February 11, 2019
Click here for details on ClinicalTrials.gov
Pacanalotamab
AMG 420
BI 836909
- New York: Memorial Sloan-Kettering Cancer Center New York
- Massachusetts: Massachusetts General Hospital Boston
- North Carolina: Wake Forest Baptist Health Winston-Salem
Locations
United States, Illinois
United States, Massachusetts
United States, New York
United States, North Carolina
Australia, New South Wales
Australia, Victoria
Europe
Belgium
Switzerland
Asia
Japan